ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO1089

Urinary Soluble CD163 as a Biomarker for Lupus Nephritis

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Suwa, Junya, Gunma University Graduate School of Medicine, Maebashi, Japan
  • Ikeuchi, Hidekazu, Gunma University Graduate School of Medicine, Maebashi, Japan
  • Kajiyama, Hiroshi, Saitama Medical University, Saitama, Japan
  • Hamatani, Hiroko, Gunma University Graduate School of Medicine, Maebashi, Japan
  • Nakasatomi, Masao, Gunma University Graduate School of Medicine, Maebashi, Japan
  • Kaneko, Yoriaki, Gunma University Graduate School of Medicine, Maebashi, Japan
  • Sakairi, Toru, Gunma University Graduate School of Medicine, Maebashi, Japan
  • Nojima, Yoshihisa, Japan Red Cross Maebashi Hospital, Maebashi, Japan
  • Hiromura, Keiju, Gunma University Graduate School of Medicine, Maebashi, Japan
  • Mimura, Toshihide, Saitama Medical University, Saitama, Japan
Background

Recently, it has been reported that urinary soluble CD163 (UsCD163) reflects glomerular inflammation of ANCA-associated nephritis and lupus nephritis (LN). We examined the significance of UsCD163 as a biomarker for histological activity and treatment response of LN.

Methods

We investigated the levels of UsCD163 before and after treatment in 52 LN patients (49 females, median age 37 years old) who were diagnosed as ISN/RPS Class III, IV or V and treated for LN since 2010 to 2015 in Gunma University and Saitama Medical University hospitals by ELISA. We also examined whether UsCD163 could be a predictor of remission of LN.

Results

RESULTS: Levels of UsCD163/creatine (Cr) were higher in Cass IV and Class V compared to Class III: III, 2.55 (1.40-5.55); IV, 8.84 (3.05-19.1); V, 8.10 (7.14-10.3) ng/mgCr;, median, (IQR). Significant correlations were observed between levels of UsCD163/Cr and urinary protein/Cr or systemic lupus erythematosus disease activity index (SLEDAI) score, but not eGFR (r=0.421, p=0.0026; r=0.465, p<0.001; r=-0.212, p=0.143). Associations between UsCD163/Cr and histological parameters were shown in Table 1. Significant positive correlations were found between levels of UsCD163/Cr and activity index, leukocyte infiltration or cellular crescents. UsCD163/Cr levels rapidly decreased after treatments. Receiver operating characteristic analysis showed UsCD 163/Cr >17.3 ng/mgCr before treatment was predictor of the presence of cellular crescent (sensitivity 85%, specificity 44%). UsCD163/Cr <3.0 ng/mgCr before treatment was a predictive marker for early proteinuria remission defined as urine protein/Cr <0.3 g/gCr at 3 months after treatment (sensitivity 42%, specificity 92%, positive predictive value 92%, negative predictive value 69%).

Conclusion

UsCD163 could be a potential biomarker for histological activity and treatment response of LN.

Table 1. Correlation between UsCD163/Cr and histological parameters

Funding

  • Government Support - Non-U.S.